Novoheart Holdings

Novoheart is a global precision medicine company that specializes in the development of human heart-on-a-chip technologies. The company utilizes proprietary stem cell and tissue engineering techniques to create the Myocardia™ platform, which includes the world's first "human heart-in-a-jar." These bioengineered human heart constructs are used by pharmaceutical companies for drug discovery, toxicity testing, and disease modeling, providing more accurate human-specific data compared to traditional animal models. By bridging the gap between preclinical research and clinical trials, Novoheart aims to increase the efficiency and safety of cardiovascular drug development. The company's technology is particularly valuable for modeling complex conditions such as heart failure and rare genetic cardiomyopathies.